Document is current
Any future updates will be listed below
-
Authors
Zhao, Yan
Zhang, Litao
Wu, Liming
Yang, Bin
Wang, Jinyan
Li, Yumei
Diao, Qingchun
Li, Jingyi
Sun, Qing
Zhu, Xiaohong
Man, Xiaoyong
Wang, Lihua
Feng, Yanyan
Cai, Tao
Zeng, Huiming
Li, Linfeng
Lu, Jianyun
Ren, Hong
Li, Fuqiu
Lu, Qianjin
Tao, Xiaohua
Xiao, Rong
Ji, Chao
Liang, Chao
Qiu, Yanping
Chen, Bo
Zhang, Jianzhong https://orcid.org/0000-0002-5485-682X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05265923 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial
https://doi.org/10.1007/s12325-025-03284-7
-
Funding
Funding for this research was provided by:
Keymed Biosciences (Chengdu) Co., Ltd.
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 11 June 2025
First Online: 12 July 2025
Declarations
:
: Chao Liang and Yanping Qiu are employees of Keymed Biosciences (Chengdu) Co., Ltd. Bo Chen is a shareholder of Keymed Biosciences (Chengdu) Co., Ltd. Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chao Ji, and Jianzhong Zhang have nothing to disclose.
: This trial was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines issued by the National Medical Products Administration. The study protocol and amendments were approved by the ethics committee of Peking University People’s Hospital and the other participating centers.
